Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Vaccinations

Vaccinations

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Haploidentical allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma in the era of novel agents: a single-center experience.

Leukemia & lymphoma·2026

Same author

Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials.

Blood cancer journal·2025

Same author

Erratum: Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Same author

Immunogenicity and safety of a meningococcal a conjugate vaccine administered with routine EPI vaccines in African infants and toddlers.

Vaccine·2025

Same author

Development of MenFive®, an affordable pentavalent meningococcal conjugate vaccine (ACYWX) for Africa and beyond.

Human vaccines & immunotherapeutics·2025

Same author

WHO defeating meningitis symposium, 3rd international symposium on Streptococcus agalactiae disease (ISSAD) in Rio de Janeiro, Brazil: State-of-the-art overview of S. agalactiae meningitis.

Vaccine·2025

Search research articles

Related Experiment Video

Updated: Feb 19, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

Lessons from the Meningitis Vaccine Project.

F Marc LaForce¹, Mamoudou Djingarey², Simonetta Viviani³

¹1 Serum Institute of India Pvt. Ltd. , Pune, India .

Viral Immunology

|November 9, 2017

Summary

The Meningitis Vaccine Project developed MenAfriVac, a Group A meningococcal conjugate vaccine, successfully eliminating infections in sub-Saharan Africa. This project offers valuable lessons for vaccine development in resource-poor settings.

Keywords:

meningitis partnership vaccine development

More Related Videos

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

Related Experiment Videos

Last Updated: Feb 19, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

Area of Science:

Vaccinology
Global Health
Preventive Medicine

Background:

Group A meningococcal meningitis poses a significant threat in sub-Saharan Africa's meningitis belt.
The Meningitis Vaccine Project (MVP) was established to address this public health challenge.

Purpose of the Study:

To describe the development, licensure, and introduction of the MenAfriVac vaccine.
To highlight key success factors and lessons learned from the MVP for future vaccine initiatives in resource-poor countries.

Main Methods:

The project involved a multi-stakeholder partnership including PATH, the World Health Organization (WHO), and the Gates Foundation.
Development included clinical trials in Africa and India, regulatory approvals, and large-scale vaccination campaigns.
Engagement with African countries and regional bodies was central throughout all project phases.

Main Results:

The affordable Group A meningococcal conjugate vaccine, MenAfriVac, was successfully developed, licensed, and introduced.
Over 260 million Africans aged 1–29 received the vaccine between 2010 and 2016.
Dramatic public health impact achieved through the elimination of Group A meningococcal infections in areas with scaled vaccination.

Conclusions:

The MVP's success demonstrates the feasibility of developing and implementing effective vaccines in resource-poor settings.
Key elements for success include strong partnerships, sustained funding, country engagement, and navigating regulatory hurdles.
Lessons learned from the MVP can inform future vaccine development and deployment strategies globally.